Sanofi (SNYNF) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The Sanofi study, officially titled “A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP),” tests a new add-on drug in patients not well controlled on standard nose sprays. It aims to show if lunsekimig can safely reduce symptoms and polyp burden in a hard-to-treat group, an area where biologic drugs have begun to reshape care.
The intervention is lunsekimig, also known as SAR443765, given as a subcutaneous injection every four weeks. It is used on top of usual intranasal steroid spray, with the goal of improving sinus symptoms and reducing the need for surgery or systemic steroids compared with placebo.
The trial is an interventional Phase 2 proof-of-concept study with randomized allocation into two parallel arms, lunsekimig or placebo. It is double-blind with masking of participants, care teams, investigators, and outcome assessors, and its main purpose is to test whether the treatment works and is safe enough to justify larger late-stage trials.
The study runs for about 40 weeks per patient, including screening, 24 weeks of treatment, and 12 weeks of follow-up, giving a solid view of medium-term effects. It was first submitted on June 6, 2024, marked as completed by the time of the latest registry entry, and last updated on April 27, 2026, signaling that data cleaning and internal review are likely underway.
For investors, the completion and recent update of this Phase 2 trial are a key de-risking step for Sanofi’s immunology pipeline and may support sentiment toward SNYNF if headline efficacy and safety are competitive. In CRSwNP, Sanofi already co-markets Dupixent, and positive proof-of-concept data for lunsekimig could extend its respiratory and inflammation franchise while responding to competition from other biologics targeting similar patient populations.
The trial is now completed and recently updated on the registry, and investors can track future milestones and emerging data summaries on the ClinicalTrials portal for more detail.
To learn more about SNYNF’s potential, visit the Sanofi drug pipeline page.